Active Ingredient

Phase 2Small molecule

CClinical Research Centre, Malaysia

Active Ingredient is one of 30 small molecule programs targeting Pneumonia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PneumoniaRecruiting

PneumoniaPhase 2

Recruiting

Competition

Competitive Landscape

152 competitors in Pneumonia

#DrugCompanyPhaseTrials

Innohep

Jazz Pharmaceuticals

Preclinical

1 2

Zantac 150

CChattem

Preclinical

2 3

Retrovir

BBp Consulting, Inc

Preclinical

2 4

Primsol

CConrado Roberto Hoffmann Filho

Preclinical

2 5

Cancidas

FFresenius Kabi Taiwan Ltd.

Preclinical

1 6

Salbutamol

GSK

Preclinical

1 7

Gantanol

CConrado Roberto Hoffmann Filho

Preclinical

2 8

Active Ingredient

CClinical Research Centre, Malaysia

Phase 2

1 9

Combination Therapy

Chong Kun Dang Pharmaceutical

Preclinical

1 10

Angiotensin-Converting Enzyme Inhibitors

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pneumonia1 trial

Effect of High Dose Intravenous Vitamin C in Severe Pneumonia

Recruiting·—·Phase 2·NCT05842382·484 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Active Ingredient. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Active Ingredient compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Active Ingredient. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clinical Research Centre, Malaysia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CClinical Research Centre, Malaysia

Active Ingredient

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pneumonia1 trial

References

Drug Info

Quick Facts

Related News